Management of Coagulation and Anticoagulation in Liver... : Liver Transplantation (original) (raw)
Review Articles
1Center for the Study of Coagulation in Liver Disease, Division of Gastroenterology and HepatologyUniversity of Virginia Health System, University of VirginiaCharlottesvilleVA
*Address reprint requests to Patrick Northup, M.D., M.H.S., Center for the Study of Coagulation in Liver Disease, Division of Gastroenterology and Hepatology, University of Virginia Health System, University of Virginia, JPA and Lee Street, MSB 2145 West Complex, Charlottesville, VA. Telephone: 434‐243‐2718; FAX: 434‐244‐9454;
E‐mail: [email protected]
Abstract
Hemostasis is a complex balance of clot formation and dissolution that is largely modulated by protein synthesis and degradation in the liver. In the state of end‐stage liver disease, there is a disruption of the hemostatic system due to hepatic protein synthetic dysfunction. Because historical clinical laboratory testing often only analyzes a portion of the hemostasis system, the clinician may be misled into believing that cirrhosis patients are imbalanced with a tendency toward bleeding. The modern understanding of hemostasis in cirrhosis involves a rebalance of hemostasis with a tenuous equilibrium between clotting and bleeding, but an equilibrium nonetheless. The clinician should be aware of this rebalance and not depend on limited and flawed laboratory testing in making judgments about the tendency for bleeding or clotting based on these values alone. Prophylactic protocol transfusions including large doses of fresh frozen plasma to “correct” the international normalized ratio are good examples of ineffective and potentially harmful interventions based on an outdated understanding of hemostasis in cirrhosis. Conversely, a thrombotic state is increasingly recognized in patients with cirrhosis, and conditions such as portal vein thrombosis are now becoming important therapeutic targets in many liver transplantation (LT) candidates and other patients with chronic liver disease. This article will introduce the reader to the modern understanding of hemostasis in cirrhosis, describe the common pitfalls and opportunities in treating hemostasis system abnormalities in the LT candidate particularly in regards to preprocedural prophylactic transfusions, and discuss therapeutic targets and interventions for thrombotic complications in the end‐stage liver disease population.
© 2018 The Authors. Liver Transplantation published by Wiley Periodicals, Inc. on behalf of American Association for the Study of Liver Diseases.